GO:0006991 response to sterol depletion: Cellular Stress Response, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0006991 (response to sterol depletion) describes any cellular or organismal process triggered by deprivation of sterols, a class of steroids with a hydroxyl group and hydrocarbon side-chain.
• Sterol depletion activates SREBP2 (SREBF2) and the mevalonate pathway to restore cholesterol biosynthesis, while also engaging mTORC1, XBP1, and inflammasome-related signaling [1,2,6].
• Key genes include SREBF2, HMGCR, INSIG1, SCAP, LDLR, and NPC1, which coordinate sterol sensing, uptake, and synthesis [5,8].
• Dysregulated sterol depletion responses contribute to cancer progression, atherosclerosis, neurodegeneration, and immune dysfunction [2,4,6,7].
• Experimental models for studying GO:0006991 include statin or cyclodextrin-induced depletion, SREBF2 knockout, and point mutations in sterol-sensing domains [4,8].
• CRISPR knockout, knock-in, and overexpression cell models enable causal dissection of sterol depletion response genes in disease contexts [1,5].
Description
Response to sterol depletion (GO:0006991) is a biological process that encompasses the cellular and organismal changes triggered when sterols become scarce. Sterols are a group of steroids characterized by one or more hydroxyl groups and a hydrocarbon side-chain, with cholesterol being the most abundant in mammalian cells. This process is essential for maintaining membrane integrity, lipid homeostasis, and cellular survival under metabolic stress [5,7]. Researchers study GO:0006991 because it intersects with major diseases including cancer, atherosclerosis, and neurodegeneration, and because it is a central node in lipid metabolism and immune regulation [2,4,6]. Understanding how cells sense and respond to sterol depletion provides insights into fundamental cell biology and identifies therapeutic targets.
response to sterol depletion At A Glance
| GO ID | GO:0006991 |
|---|---|
| GO term | response to sterol depletion |
| Ontology | biological_process |
| Synonym | sterol depletion response |
| Major function | Cellular and organismal adaptation to deprivation of sterols, including transcriptional and metabolic reprogramming |
| Key regulators | SREBF2, SCAP, INSIG1, HMGCR, mTORC1, XBP1 [1,2,5] |
| Associated diseases | Cancer, atherosclerosis, neurodegeneration, immune disorders [2,4,6,7] |
| Experimental inducers | Statins, methyl-beta-cyclodextrin, sterol-like drugs [4,8] |
What Is GO:0006991?
GO:0006991, response to sterol depletion, is defined as any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stimulus indicating deprivation of sterols. Sterols are a group of steroids characterized by the presence of one or more hydroxyl groups and a hydrocarbon side-chain in the molecule. This term captures the signaling, transcriptional, and metabolic reprogramming events that occur when sterol levels fall below a threshold, including activation of sterol regulatory element-binding proteins (SREBPs) and downstream target genes [5,8].
Why Is response to sterol depletion Important in Cell Biology?
Response to sterol depletion is critical because sterols are essential for membrane structure, hormone synthesis, and cell signaling. When sterols are depleted, cells must rapidly adjust lipid synthesis, uptake, and storage to survive. This process is hijacked in cancer to support proliferation and immune evasion, and its failure contributes to atherosclerosis and neurodegeneration [2,6,7]. Understanding GO:0006991 therefore has broad implications for metabolic diseases, cancer therapy, and immunology [4,8].
• Maintains membrane integrity and fluidity under sterol-limiting conditions.
• Activates SREBP2-mediated cholesterol biosynthesis to restore sterol levels [5,8].
• Links lipid metabolism to mTORC1 signaling and aging.
• Modulates inflammasome activation and vascular inflammation.
• Supports cancer cell survival and immunosuppressive reprogramming.
• Sensitizes cancer cells to chemotherapy when sterol depletion is induced.
• Contributes to neurodegeneration through membrane dysfunction.
• Provides targets for statin-based and sterol-like drug therapies.
• Influences liver regeneration and hepatocyte metabolic remodeling.
• Serves as a model for studying cellular stress responses and lipid sensing [1,5].
What Happens During response to sterol depletion?
Sterol sensing and SREBP2 activation
In simple terms: When cholesterol runs low, cells switch on a master regulator called SREBP2 to make more cholesterol.
Sterol depletion is sensed by the SREBP cleavage-activating protein (SCAP), which undergoes a conformational change when sterol levels drop, allowing it to escort SREBP2 (SREBF2) from the endoplasmic reticulum to the Golgi [5,8]. In the Golgi, SREBP2 is cleaved by site-1 and site-2 proteases, releasing its N-terminal fragment that translocates to the nucleus and activates genes of the mevalonate pathway, including HMGCR and LDLR [5,8]. This transcriptional response is a hallmark of GO:0006991 and is conserved from yeast to humans.
Mevalonate pathway and cholesterol biosynthesis
In simple terms: The cell ramps up the production line that makes cholesterol from scratch.
Upon SREBP2 activation, enzymes such as HMGCR, MVK, and FDFT1 are upregulated to increase de novo cholesterol biosynthesis. This metabolic remodeling is essential for restoring sterol levels and is observed in hepatocytes during liver regeneration. In cancer cells, enhanced cholesterol production driven by XBP1 supports immunosuppressive reprogramming of myeloid cells. Sterol-like drugs can inhibit SREBP2 nuclear translocation and potentiate statin-triggered cell death, highlighting the therapeutic relevance of this pathway.
mTORC1 signaling and autophagy
In simple terms: Sterol depletion also talks to the cell's growth-control center, mTORC1, which can affect aging.
mTORC1 is a key nutrient sensor that integrates sterol availability with growth and autophagy. YTHDF1 has been shown to differentiate the contributing roles of mTORC1 in aging, linking sterol depletion responses to longevity pathways. Under sterol depletion, mTORC1 activity can be modulated, influencing protein synthesis and autophagic flux. This crosstalk ensures that cells adapt their biosynthetic capacity to available sterol resources.
Inflammatory and immune signaling
In simple terms: Low sterol levels can set off inflammation or change how immune cells behave.
Desmosterol, a sterol intermediate, suppresses macrophage inflammasome activation and protects against vascular inflammation and atherosclerosis. Sterol depletion can therefore relieve this suppression, promoting inflammatory responses. In cancer, XBP1-driven cholesterol production promotes immunosuppressive reprogramming of intratumoral myeloid cells, linking sterol metabolism to immune evasion. These findings place GO:0006991 at the interface of lipid metabolism and immunity [2,6].
Membrane remodeling and stress responses
In simple terms: The cell adjusts its membranes and stress pathways to cope with less cholesterol.
Sterol depletion alters membrane fluidity and organization, which can trigger stress responses such as the unfolded protein response and DNA damage response [4,7]. In gallbladder cancer, cholesterol depletion sensitizes cells to cisplatin by impairing the DNA damage response. In LRRK2-associated Parkinson's disease, membrane dysfunction is a central mechanism, and sterol depletion may exacerbate this pathology. These examples illustrate how GO:0006991 integrates membrane biology with cellular stress pathways [4,7].
Key Genes Involved in GO:0006991 response to sterol depletion
The following genes and proteins are central to the response to sterol depletion, based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| SREBF2 | Master transcription factor for cholesterol biosynthesis | Knockout reduces sterol depletion response; target for statin combination therapy [5,8] |
| SCAP | Sterol sensor that escorts SREBP2 to Golgi | Point mutations in sterol-sensing domain alter response |
| INSIG1 | Retains SREBP2 in ER under high sterol | Overexpression blocks SREBP2 activation |
| HMGCR | Rate-limiting enzyme in mevalonate pathway | Target of statins; knockout affects cholesterol synthesis [5,8] |
| LDLR | Mediates cholesterol uptake from LDL | Upregulated upon sterol depletion; knockout models hypercholesterolemia |
| XBP1 | Transcription factor driving cholesterol production in cancer | Knockout impairs immunosuppressive reprogramming |
| mTORC1 | Nutrient sensor integrating sterol availability | Modulates aging and autophagy |
| YTHDF1 | m6A reader linking mTORC1 to aging | Knockout extends lifespan in some models |
| NPC1 | Intracellular cholesterol trafficking | Mutations cause Niemann-Pick disease; affects sterol depletion response |
| LRRK2 | Kinase involved in membrane trafficking | Mutations linked to Parkinson's disease and membrane dysfunction |
| CASP1 | Inflammasome component suppressed by desmosterol | Knockout reduces inflammation in atherosclerosis models |
| IL1B | Inflammatory cytokine downstream of inflammasome | Readout of sterol depletion-induced inflammation |
| ABCA1 | Cholesterol efflux transporter | Regulated by sterol status; affects HDL levels |
| SREBF1 | Transcription factor for fatty acid synthesis | Crosstalk with SREBP2 in lipid homeostasis |
| FDFT1 | Squalene synthase in cholesterol biosynthesis | Upregulated upon sterol depletion |
| MVK | Mevalonate kinase in cholesterol pathway | Mutations cause mevalonate kinase deficiency |
| SCD | Stearoyl-CoA desaturase for fatty acid desaturation | Modulated by sterol depletion to maintain membrane fluidity |
How Is response to sterol depletion Regulated?
Response to sterol depletion is regulated at multiple levels. The SREBP2-SCAP-INSIG1 axis provides rapid feedback control: when sterols are abundant, INSIG1 retains SCAP-SREBP2 in the endoplasmic reticulum; upon depletion, SCAP changes conformation, releasing SREBP2 for Golgi processing [5,8]. mTORC1 signaling integrates sterol availability with growth and autophagy, and YTHDF1 modulates this crosstalk in aging. Inflammatory signaling through desmosterol and the inflammasome provides another layer of regulation, where sterol intermediates suppress caspase-1 activation. Additionally, XBP1 drives cholesterol production in cancer cells, linking ER stress to sterol metabolism. These regulatory mechanisms ensure that cells adapt to sterol fluctuations while avoiding lipotoxicity [1,5,6].
response to sterol depletion and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| SREBF2 | Cancer, hypercholesterolemia | Knockout and point-mutation cell lines [5,8] |
| XBP1 | Cancer immunosuppression | Knockout in tumor cells |
| CASP1 | Atherosclerosis, inflammation | Knockout macrophages |
| LRRK2 | Parkinson's disease | Knock-in of G2019S mutation |
| SLC13A2 | Liver regeneration, metabolic disease | Overexpression in hepatocytes |
Cancer
Sterol depletion responses are frequently reprogrammed in cancer. XBP1-driven cholesterol production in cancer cells promotes immunosuppressive reprogramming of intratumoral myeloid cells, supporting tumor growth. Conversely, inducing sterol depletion with statins or sterol-like drugs can sensitize cancer cells to chemotherapy, as shown in gallbladder cancer where cholesterol depletion impairs the DNA damage response and increases cisplatin sensitivity. In prostate cancer, sterol-like drugs potentiate statin-triggered cell death by inhibiting SREBP2 nuclear translocation. These findings highlight the therapeutic potential of targeting GO:0006991 in oncology [2,4,8].
Atherosclerosis and vascular inflammation
Desmosterol, a sterol intermediate, suppresses macrophage inflammasome activation and protects against vascular inflammation and atherosclerosis. When sterol depletion occurs, this suppression is relieved, leading to increased inflammasome activity and IL-1beta production, which exacerbates vascular inflammation. Therefore, the response to sterol depletion is a double-edged sword in cardiovascular disease: it is necessary for cholesterol homeostasis but can promote inflammation when dysregulated.
Neurodegeneration
Membrane dysfunction is a central mechanism in LRRK2-associated Parkinson's disease, and sterol depletion may contribute to this pathology. LRRK2 mutations, such as G2019S and I1371V, affect membrane trafficking and lipid homeostasis, potentially impairing the response to sterol depletion. This suggests that GO:0006991 is relevant to neurodegenerative disorders where lipid metabolism is perturbed.
Metabolic and liver diseases
SLC13A2 promotes hepatocyte metabolic remodeling and liver regeneration by enhancing de novo cholesterol biosynthesis, linking sterol depletion responses to liver physiology. Dysregulation of this pathway may contribute to metabolic liver diseases and affect regenerative capacity. Understanding how hepatocytes respond to sterol depletion could inform therapies for liver injury and metabolic syndrome.
From response to sterol depletion-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does SREBF2 mediate sterol depletion-induced cholesterol synthesis? | SREBF2 knockout cell line |
| How do point mutations in SCAP affect sterol sensing? | SCAP point-mutation knock-in |
| Does XBP1 drive immunosuppression in tumors? | XBP1 knockout cancer cells |
| Can desmosterol suppress inflammasome in vivo? | CASP1 knockout mice |
| What is the role of LRRK2 G2019S in membrane dysfunction? | LRRK2 G2019S knock-in neurons |
| Does SLC13A2 overexpression enhance liver regeneration? | SLC13A2 overexpression hepatocytes |
How to Study the response to sterol depletion Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | Global gene expression changes | Identify SREBP2 targets upon sterol depletion |
| Lipidomics (LC-MS) | Cholesterol and sterol intermediates | Quantify desmosterol and cholesterol levels |
| Western blot | SREBP2 cleavage, inflammasome activation | Validate knockout effects [2,6] |
| Immunofluorescence | SREBP2 localization, membrane sterols | Track ER-to-Golgi transport [5,7] |
| CRISPR screening | Genes required for sterol depletion response | Identify novel regulators |
| Proteomics | Protein abundance and modifications | Assess mTORC1 and LRRK2 signaling [1,7] |
| Reporter assays | SREBP2 transcriptional activity | Measure sterol depletion response |
Transcriptomic profiling
RNA-seq is widely used to measure global gene expression changes upon sterol depletion, revealing upregulation of SREBP2 target genes such as HMGCR and LDLR [5,8]. This method can identify novel regulators of GO:0006991 and validate CRISPR knockout effects [1,5].
Lipidomics and sterol quantification
Mass spectrometry-based lipidomics quantifies cholesterol and intermediate sterols like desmosterol, providing direct evidence of sterol depletion and compensatory synthesis [6,8]. This is essential for confirming the efficacy of statins or cyclodextrin treatments [4,8].
Proteomics and phosphoproteomics
Proteomic approaches can assess SREBP2 cleavage, mTORC1 activity, and inflammasome activation at the protein level [1,6]. Phosphoproteomics reveals signaling changes downstream of sterol depletion, such as LRRK2 phosphorylation.
Imaging and membrane dynamics
Fluorescence microscopy with sterol-binding dyes (e.g., filipin) visualizes cholesterol distribution and membrane remodeling during sterol depletion. Live-cell imaging can track SREBP2-GFP translocation from ER to Golgi.
How CRISPR Can Be Used to Study GO:0006991 response to sterol depletion
Knockout
CRISPR knockout of SREBF2, XBP1, or CASP1 enables loss-of-function studies to determine their causal roles in response to sterol depletion [2,5,6]. For example, SREBF2 knockout cells fail to upregulate cholesterol biosynthesis genes upon statin treatment. XBP1 knockout in cancer cells reduces immunosuppressive reprogramming.
Point Mutation
Point mutations in sterol-sensing domains of SCAP or NPC1 can be introduced to mimic disease-associated variants and study their impact on sterol depletion sensing [5,7]. LRRK2 G2019S knock-in models reveal membrane dysfunction relevant to Parkinson's disease.
Knock-in
Knock-in of tagged SREBP2 or SCAP allows real-time tracking of protein localization and cleavage during sterol depletion. This approach can also be used to introduce disease-relevant mutations in LRRK2 or NPC1.
Overexpression
Overexpression of SLC13A2 or constitutively active SREBP2 can enhance cholesterol biosynthesis and promote liver regeneration or cancer cell survival [2,5]. Overexpression models help test sufficiency of a gene in driving the sterol depletion response.
How EDITGENE Supports response to sterol depletion Research
Researchers studying response to sterol depletion-related genes often need to determine whether a candidate gene is causally involved in sensing, signaling, or metabolic adaptation. EDITGENE provides CRISPR-based cell models and screening services to dissect these mechanisms with precision.
Contact EDITGENE today to design your custom CRISPR model for response to sterol depletion research.
Frequently Asked Questions About response to sterol depletion
What is GO:0006991 response to sterol depletion?
GO:0006991 is a biological process describing any cellular or organismal change triggered by deprivation of sterols, including transcriptional and metabolic adaptations.
What genes are involved in response to sterol depletion?
Key genes include SREBF2, SCAP, INSIG1, HMGCR, LDLR, XBP1, and CASP1, which regulate cholesterol synthesis, uptake, and inflammation [2,5,6].
How does SREBP2 respond to sterol depletion?
Upon sterol depletion, SCAP escorts SREBP2 to the Golgi for cleavage, releasing a transcription factor that activates cholesterol biosynthesis genes [5,8].
What diseases are linked to sterol depletion response?
Cancer, atherosclerosis, neurodegeneration, and liver metabolic diseases are associated with dysregulated sterol depletion responses [2,4,6,7].
What experimental models study sterol depletion?
Statin or cyclodextrin treatment, SREBF2 knockout, and point mutations in SCAP or LRRK2 are common models [4,5,7,8].
How is mTORC1 involved in sterol depletion?
mTORC1 integrates sterol availability with growth and autophagy, and YTHDF1 modulates this crosstalk in aging.
Can CRISPR be used to study response to sterol depletion?
Yes, CRISPR knockout, knock-in, and overexpression models enable causal dissection of genes in GO:0006991 [1,2,5].
What is the role of desmosterol in sterol depletion?
Desmosterol suppresses inflammasome activation and protects against atherosclerosis, but its levels drop during sterol depletion.
How does cholesterol depletion affect cancer therapy?
Cholesterol depletion sensitizes cancer cells to cisplatin by impairing DNA damage response, suggesting combination strategies.
What methods measure sterol depletion response?
RNA-seq, lipidomics, proteomics, and imaging are used to measure transcriptional, metabolic, and signaling changes [1,5,6,7].
Conclusion
Response to sterol depletion (GO:0006991) is a fundamental biological process that coordinates lipid metabolism, signaling, and immune responses. Its dysregulation contributes to cancer, atherosclerosis, neurodegeneration, and metabolic diseases [2,4,6,7]. CRISPR-based models and multi-omics approaches are essential for dissecting the underlying mechanisms and identifying therapeutic targets [1,5,8]. EDITGENE provides comprehensive services to accelerate research in this field.
References
- 1. Xu C et al.. 2025. YTHDF1 differentiates the contributing roles of mTORC1 in aging.. Mol Cell 85(11):2194-2210.e8 PMID: 40441158
- 2. Yang Z et al.. 2022. Cancer cell-intrinsic XBP1 drives immunosuppressive reprogramming of intratumoral myeloid cells by promoting cholesterol production.. Cell Metab 34(12):2018-2035.e8 PMID: 36351432
- 4. Zhang Y et al.. 2019. Cholesterol depletion sensitizes gallbladder cancer to cisplatin by impairing DNA damage response.. Cell Cycle 18(23):3337-3350 PMID: 31599189
- 5. Shi L et al.. 2025. SLC13A2 promotes hepatocyte metabolic remodeling and liver regeneration by enhancing de novo cholesterol biosynthesis.. EMBO J 44(5):1442-1463 PMID: 39824985
- 6. Zhang X et al.. 2021. Desmosterol suppresses macrophage inflammasome activation and protects against vascular inflammation and atherosclerosis.. Proc Natl Acad Sci U S A 118(47) PMID: 34782454
- 7. Singh K et al.. 2026. Membrane Dysfunction as a Central Mechanism in LRRK2-Associated Parkinson's Disease: Comparative Analysis of G2019S and I1371V Variants.. Cells 15(4) PMID: 41744785
- 8. Dos Santos DZ et al.. 2024. Sterol-like drugs potentiate statin-triggered prostate cancer cell death by inhibiting SREBP2 nuclear translocation.. Biomed Pharmacother 177:116934 PMID: 38889639
